Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $86.40 USD
Change Today -0.25 / -0.29%
Volume 1.6M
NVS On Other Exchanges
New York
SIX Swiss Ex
SIX Swiss Ex
As of 8:04 PM 11/24/15 All times are local (Market data is delayed by at least 15 minutes).
text size: T | T
Back to Snapshot
Company Description

Contact Info

Lichtstrasse 35

Basel, 4056


Phone: 41 61 324 11 11


daily disposables and color contact lenses includes its Air Optix, Dailies and Freshlook brands. The Dailies product line includes Dailies Total1 lenses, a water gradient contact lens. The company’s Air Optix product line includes the new Air Optix Colors silicone hydrogel contact lenses. The company’s contact lens care solutions business includes the Opti-Free line of multi-purpose disinfecting solutions and drops, as well as the Clear Care and AOSept Plus hydrogen peroxide lens care solutions. Sales and Marketing: The Alcon division conducts sales and marketing activities worldwide organized under five operating regions (the U.S., Europe/the Middle East/Africa, Latin America/Caribbean/Canada, Asia and Japan). Research and Development In 2014, the Alcon division expensed $0.9 billion on research and development activities. SANDOZ The Sandoz division engages in developing, manufacturing and marketing generic pharmaceutical products, follow-on biopharmaceutical products known as biosimilars, and drug substances that are not protected by valid and enforceable third-party patents. As of December 31, 2014, the Sandoz division sold products in approximately 160 countries. The Sandoz division is organized in three franchises: Retail Generics, Anti-Infectives, and Biopharmaceuticals & Oncology Injectables. In Retail Generics, Sandoz division develops, manufactures and markets active ingredients and finished dosage forms of pharmaceuticals to third parties. Retail Generics includes the specialty areas of Dermatology, Respiratory and Ophthalmics, as well as cardiovascular, metabolism, central nervous system, pain, gastrointestinal, and hormonal therapies. In Anti-Infectives, Sandoz division manufactures active pharmaceutical ingredients and intermediates—mainly antibiotics—for internal use by Retail Generics and for sale to third-party customers. In Biopharmaceuticals, Sandoz division develops, manufactures and markets protein- or other biotechnology-based products (known as biosimilars or follow-on biologics) and provides biotechnology manufacturing services to other companies, and in Oncology Injectables, Sandoz division develops, manufactures and markets cytotoxic products for the hospital market. In 2014, Sandoz division launched 28 new products in the U.S., including authorized generic versions of its Pharmaceuticals Division products Diovan (valsartan), Focalin XR (dexmethylphenidate ER) and TOBI (tobramycin inhalation solution, USP); as well as cyclophosphamide injection, USP; calcipotriene and betamethasone dipropionate ointment (Taclonex, Leo Pharma); adapalene gel (Differin, Galderma Laboratories); lansoprazole capsules, amoxicillin capsules, USP, and clarithromycin tablets, USP (PREVPAC, Takeda Pharmaceuticals); the injectable decitabine (Dacogen, Eisai), and Kerydin (tavaborole) topical solution, 5% after obtaining exclusive rights from Anacor Pharmaceuticals to commercialize it in the U.S. through Sandoz's branded dermatology business, PharmaDerm. Furthermore, Sandoz division reached an agreement with Upsher-Smith to obtain exclusive U.S. distribution rights for its branded potassium chloride product line, Klor-Con. Main product launches in various European countries include AirFluSal Forspiro, a respiratory product that offers the combination of salmeterol (a long-acting inhaled beta2-agonist) and fluticasone propionate (an inhaled corticosteroid) for asthma and chronic obstructive pulmonary disease patients in an inhalation device, Vitaros (alprostadil), a topical therapy for erectile dysfunction, escitalopram (Cipralex, Lundbeck), and mometasone (the generic version of Nasonex, Merck Sharp & Dohme), which was launched in additional European countries in 2014. In 2013, Sandoz division received Danish marketing authorization for AirFluSal Forspiro. AirFluSal Forspiro has received marketing authorizations in a total of 15 European countries, as well as South Korea and Mexico, and been launched in four European countries and South Korea. New Products Sandoz division launched various products in 2014, including the following: Valsartan (Diovan); Cyclophosphamide injec


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
NVS:US $86.40 USD -0.25

NVS Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Amgen Inc $162.78 USD +0.31
Gilead Sciences Inc $106.57 USD +0.21
Johnson & Johnson $102.04 USD -0.73
Nestle SA SFr.75.10 CHF +0.30
Pfizer Inc $31.97 USD +0.64
View Industry Companies

Industry Analysis


Industry Average

Valuation NVS Industry Range
Price/Earnings 25.4x
Price/Sales 4.1x
Price/Book 2.7x
Price/Cash Flow 11.4x
TEV/Sales 3.5x

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact NOVARTIS AG-SPONSORED ADR, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at